AI-Discovered Drugs in Clinical Trials 2026: Full Pipeline
A data-driven 2026 survey of AI-discovered drugs in clinical trials, mapping Insilico Medicine, Recursion Pharmaceuticals, Isomorphic Labs, success rates, funding, and named case studies.
Back to Articles
Articles tagged with “insilico-medicine”
Insilico-Bora $2.5B Alliance: AI Drug Discovery Meets CDMO
Analyzes the July 2026 Insilico Medicine and Bora Pharmaceuticals $2.5 billion alliance: deal structure, AI-in-CDMO manufacturing shift, AI literacy mandates, and 2026 market data.
AI Drug Discovery FDA Approvals: The 2026 Reality Check
Analyzes whether AI has discovered any FDA-approved drugs as of 2026, covering Insilico Medicine's rentosertib Phase III trial, Takeda's zasocitinib, clinical success rates, and billions in AI drug discovery investment.
Eli Lilly AI Partnerships: Strategy & Timeline Analysis
Analyze Eli Lilly's 2026 AI partnership map and co-innovation strategy. Learn how collaborations with NVIDIA, Insilico, and Chai advance drug discovery.
INS018_055 Phase IIa Results: First AI-Designed Drug
Analyze the Phase IIa clinical trial results of INS018_055 (rentosertib), the first AI-designed drug by Insilico Medicine targeting TNIK for IPF treatment.
Insilico Pharma.AI: AI Drug Discovery Platform Analysis
Analyze Insilico Medicine's Pharma.AI platform for AI drug discovery. Learn how PandaOmics, Chemistry42, and MMAI Gym integrate for target and molecule design.
AI Drug Discovery: The $2.75B Lilly-Insilico Deal Analysis
Analyze the $2.75B partnership between Eli Lilly and Insilico Medicine. Understand how generative AI impacts pharma R&D strategy and drug commercialization.